Because every cancer patient deserves the best shot at a cure
BetaGlue™ Therapeutics introduces YntraDose™ – an innovative radiotherapy platform for the targeted and personalised treatment of solid tumours.
By offering a novel easy-to-use interventional oncology treatment option YntraDose™ is set to become the new standard of care for a wide range of solid tumour cancer patient groups where current approaches fall short.
Why we’re here
Today, radiotherapy treatment options have varying impact. Stereotactic Body Radiotherapy (SBRT) and Proton Beam Radiotherapy (PBRT), face challenges associated with internal organ movement and patient throughput. They also require substantial investment in specialised equipment and infrastructure, making them less accessible.
YntraDose represents a ground-breaking solution by circumventing these limitations.
It presents a potential new standard of care that aims to enhance treatment efficacy, reduce side effects, and make personalised cancer treatment more accessible to patients worldwide.
Our mission
By offering a novel easy-to-use interventional oncology treatment option YntraDose is set to become the new standard of care for a wide range of solid tumour cancer patient groups where current approaches fall short.
Contact us
To find out more about our pipeline, or to work for us, or to understand YntraDose further, get in touch with us